Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells

Jonathan Metts, Heath L. Bradley, Zhengqi Wang, Neil P. Shah, Reuben Kapur, Jack L. Arbiser, Kevin D. Bunting

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML). Inhibitors to FLT3 have already been tested in clinical trials, however, drug resistance limits clinical efficacy. Mutant receptor tyrosine kinases are mislocalized in the endoplasmic reticulum (ER) of AML and play an important role in the non-canonical activation of signal transducer and activator of transcription 5 (STAT5). Here, we have tested a potent new drug called imipramine blue (IB), which is a chimeric molecule with a dual mechanism of action. At 200-300 nM concentrations, IB is a potent inhibitor of STAT5 through liberation of endogenous phosphatase activity following NADPH oxidase (NOX) inhibition. However, at 75-150 nM concentrations, IB was highly effective at killing mutant FLT3-driven AML cells through a similar mechanism as thapsigargin (TG), involving increased cytosolic calcium. IB also potently inhibited survival of primary human FLT3/ITD+ AML cells compared to FLT3/ITDneg cells and spared normal umbilical cord blood cells. Therefore, IB functions through a mechanism involving vulnerability to dysregulated calcium metabolism and the combination of fusing a lipophilic amine to a NOX inhibiting dye shows promise for further pre-clinical development for targeting high risk AML.

Original languageEnglish (US)
Article number4447
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Imipramine
Myeloid Cells
Acute Myeloid Leukemia
STAT5 Transcription Factor
NADPH Oxidase
Receptor Protein-Tyrosine Kinases
Calcium
Thapsigargin
Survival
Fetal Blood
Phosphoric Monoester Hydrolases
Drug Resistance
Endoplasmic Reticulum
Amines
Blood Cells
Coloring Agents
Clinical Trials
Cytokines
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. / Metts, Jonathan; Bradley, Heath L.; Wang, Zhengqi; Shah, Neil P.; Kapur, Reuben; Arbiser, Jack L.; Bunting, Kevin D.

In: Scientific Reports, Vol. 7, No. 1, 4447, 01.12.2017.

Research output: Contribution to journalArticle

Metts, Jonathan ; Bradley, Heath L. ; Wang, Zhengqi ; Shah, Neil P. ; Kapur, Reuben ; Arbiser, Jack L. ; Bunting, Kevin D. / Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{378a7e574fa54fd9833f9132e94e5d4d,
title = "Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells",
abstract = "Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML). Inhibitors to FLT3 have already been tested in clinical trials, however, drug resistance limits clinical efficacy. Mutant receptor tyrosine kinases are mislocalized in the endoplasmic reticulum (ER) of AML and play an important role in the non-canonical activation of signal transducer and activator of transcription 5 (STAT5). Here, we have tested a potent new drug called imipramine blue (IB), which is a chimeric molecule with a dual mechanism of action. At 200-300 nM concentrations, IB is a potent inhibitor of STAT5 through liberation of endogenous phosphatase activity following NADPH oxidase (NOX) inhibition. However, at 75-150 nM concentrations, IB was highly effective at killing mutant FLT3-driven AML cells through a similar mechanism as thapsigargin (TG), involving increased cytosolic calcium. IB also potently inhibited survival of primary human FLT3/ITD+ AML cells compared to FLT3/ITDneg cells and spared normal umbilical cord blood cells. Therefore, IB functions through a mechanism involving vulnerability to dysregulated calcium metabolism and the combination of fusing a lipophilic amine to a NOX inhibiting dye shows promise for further pre-clinical development for targeting high risk AML.",
author = "Jonathan Metts and Bradley, {Heath L.} and Zhengqi Wang and Shah, {Neil P.} and Reuben Kapur and Arbiser, {Jack L.} and Bunting, {Kevin D.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-04796-1",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells

AU - Metts, Jonathan

AU - Bradley, Heath L.

AU - Wang, Zhengqi

AU - Shah, Neil P.

AU - Kapur, Reuben

AU - Arbiser, Jack L.

AU - Bunting, Kevin D.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML). Inhibitors to FLT3 have already been tested in clinical trials, however, drug resistance limits clinical efficacy. Mutant receptor tyrosine kinases are mislocalized in the endoplasmic reticulum (ER) of AML and play an important role in the non-canonical activation of signal transducer and activator of transcription 5 (STAT5). Here, we have tested a potent new drug called imipramine blue (IB), which is a chimeric molecule with a dual mechanism of action. At 200-300 nM concentrations, IB is a potent inhibitor of STAT5 through liberation of endogenous phosphatase activity following NADPH oxidase (NOX) inhibition. However, at 75-150 nM concentrations, IB was highly effective at killing mutant FLT3-driven AML cells through a similar mechanism as thapsigargin (TG), involving increased cytosolic calcium. IB also potently inhibited survival of primary human FLT3/ITD+ AML cells compared to FLT3/ITDneg cells and spared normal umbilical cord blood cells. Therefore, IB functions through a mechanism involving vulnerability to dysregulated calcium metabolism and the combination of fusing a lipophilic amine to a NOX inhibiting dye shows promise for further pre-clinical development for targeting high risk AML.

AB - Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML). Inhibitors to FLT3 have already been tested in clinical trials, however, drug resistance limits clinical efficacy. Mutant receptor tyrosine kinases are mislocalized in the endoplasmic reticulum (ER) of AML and play an important role in the non-canonical activation of signal transducer and activator of transcription 5 (STAT5). Here, we have tested a potent new drug called imipramine blue (IB), which is a chimeric molecule with a dual mechanism of action. At 200-300 nM concentrations, IB is a potent inhibitor of STAT5 through liberation of endogenous phosphatase activity following NADPH oxidase (NOX) inhibition. However, at 75-150 nM concentrations, IB was highly effective at killing mutant FLT3-driven AML cells through a similar mechanism as thapsigargin (TG), involving increased cytosolic calcium. IB also potently inhibited survival of primary human FLT3/ITD+ AML cells compared to FLT3/ITDneg cells and spared normal umbilical cord blood cells. Therefore, IB functions through a mechanism involving vulnerability to dysregulated calcium metabolism and the combination of fusing a lipophilic amine to a NOX inhibiting dye shows promise for further pre-clinical development for targeting high risk AML.

UR - http://www.scopus.com/inward/record.url?scp=85021636928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021636928&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-04796-1

DO - 10.1038/s41598-017-04796-1

M3 - Article

C2 - 28667329

AN - SCOPUS:85021636928

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 4447

ER -